SUPERNUS PHARMACEUTICALS, INC. 10-K

ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASE OF EQUITY SECURITIES. Market and Shareholder Information Our common stock has been listed on the NASDAQ Global Market under the symbol "SUPN" since May 1, 2012. On December 31, 2021, the closing price of our common stock on the NASDAQ Global Market was $29.16 per share. As of December 31, 2021, we had 19 holders of record of our common stock. The actual number of common stockholders is greater than the number of record holders and includes stockholders who are beneficial owners but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities. Dividends We have never declared or paid any cash dividends on our capital stock, and we do not currently anticipate declaring or paying cash dividends on our capital stock in the foreseeable future. We currently intend to retain all of our future earnings, if any, to finance operations. Any future determination relating to our dividend policy will be made at the discretion of our board of directors and will depend on a number of factors, including future earnings, capital requirements, financial conditions, future prospects, contractual restrictions and covenants, and other factors that our board of directors may deem relevant. Option Grants During the three-month period ended December 31, 2021, the Company granted options to employees to purchase an aggregate of 64,200 shares of common stock at a weighted average exercise price of $28.89 per share. The options are exercisable for a period of ten years from the grant date. These issuances were exempt from registration in reliance on Section 4(a)(2) of the Securities Act as transactions not involving any public offering. Performance Graph The following graph sets forth the Company's total cumulative stockholder return as compared to the NASDAQ Stock Market Composite Index and the NASDAQ Biotechnology Index for the period beginning December 31, 2015, and ending December 31, 2021. Total stockholder return assumes $100 invested at the beginning of the period in the common stock of the Company, the stocks represented in the NASDAQ Composite Index and the NASDAQ Pharmaceutical, respectively. Total return assumes reinvestment of dividends; the Company has paid no dividends on its common stock. Historical price performance should not be relied upon as indicative of future stock performance. 76 Table of Contents ________________________________________________________________ * $100 invested on 12/31/2016 in stock or index, including reinvestment of dividends. Fiscal year ending December 31. Performance Graph Data Supernus Pharmaceuticals, Inc. NASDAQ Composite Index NASDAQ Pharmaceuticals Index December 31, 2016 100.00 100.00 100.00 December 31, 2017 157.82 129.64 122.85 December 31, 2018 131.56 125.96 120.80 December 31, 2019 93.94 172.17 142.53 December 31, 2020 99.64 249.51 166.32 December 31, 2021 115.49 304.85 165.08 The performance graph and related information shall not be deemed "soliciting material" or be "filed" with the SEC, nor shall such information be incorporated by reference into any future filing under the Securities Act or the Exchange Act, except to the extent that the Company specifically incorporates it by reference into such filing. ITEM 6. RESERVED.